Onset of cardiac events / Total, n (%) Reporting odds ratio (95% confidence interval)
P-value*
Non-use of romosozumab 4,097 / 701,204 (0.6) 11.5 (8.58–15.2) <0.01
Use of romosozumab 55 / 868 (6.3)
Non-use of oral bisphosphonate 4,064 / 685,957 (0.6) 0.94 (0.76–1.16) 0.64
Use of oral bisphosphonate 90 / 16,115 (0.6)
Non-use of teriparatide 4,125 / 699,359 (0.6) 1.82 (1.22–2.63) <0.01
Use of teriparatide 29 / 2,713 (1.1)
Non-use of denosumab 4,140 / 697,883 (0.6) 0.56 (0.31–0.94) 0.03
Use of denosumab 14 / 4,189 (0.3)
Onset of cerebrovascular events / Total, n (%) Reporting odds ratio (95% confidence interval)
P-value*
Non-use of romosozumab 9,176 / 701,204 (1.3) 7.03 (5.46–8.93) <0.01
Use of romosozumab 74 / 868 (8.5)
Non-use of oral bisphosphonate 9,130 / 685,957 (1.3) 0.56 (0.46–0.67) <0.01
Use of oral bisphosphonate 120 / 16,115 (0.7)
Non-use of teriparatide 9,217 / 699,359 (1.3) 0.92 (0.63–1.30) 0.74
Use of teriparatide 33 / 2,713 (1.2)
Non-use of denosumab 9,233 / 697,883 (1.3) 0.30 (0.18–0.49) <0.01
Use of denosumab 17 / 4,189 (0.4)